title: Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides.
abstract: The principal effects of cardiac glycosides probably can be classified as parasympathomimetic or sympathomimetic. Data from animals and from man suggest that polar cardiac glycosides, such as ouabain and digoxin, possess greater parasympathomimetic (vagal) cardiac effect for a given amount of sympathomimetic (positive inotropic) cardiac effect than do less polar cardiac glycosides, such as digitoxin. Polar glycosides therefore offer some advantage in uncomplicated paroxysmal atrial tachycardia and in uncomplicated atrial flutter and atrial fibrillation when the principal desired effect is reduction in the number of atrial impulses reaching the ventricles or conversion to normal sinus rhythm. Non-polar glycosides offer an advantage when positive inotropicity is desired but when there is some degree of atrioventricular block or when inappropriate sinus bradycardia or anorexia, nausea, or vomiting are present. Ecotopic impulse formation when due to cardiac glycosides is a toxic manifestation of excessive sympathomimetic effect, but is aggravated by vagal-induced sinus bradycardia, so that both parasympathomimetic and sympathomimetic capability of cardiac glycosides must be considered when dealing with myocardial electrical instability.
mesh_terms: D000818:Animals; D000855:Anorexia / Q000139:chemically induced; D001146:Arrhythmia, Sinus / Q000139:chemically induced / Q000188:drug therapy; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001285:Atropine / Q000627:therapeutic use; D001337:Autonomic Agents / Q000494:pharmacology; D001919:Bradycardia / Q000139:chemically induced / Q000188:drug therapy; D002301:Cardiac Glycosides / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D006323:Heart Arrest / Q000139:chemically induced; D006327:Heart Block / Q000139:chemically induced; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D009325:Nausea / Q000139:chemically induced; D010277:Parasympathomimetics / Q000494:pharmacology; D012849:Sinoatrial Node / Q000187:drug effects; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000494:pharmacology; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
chemical_list: D001337:Autonomic Agents; D002301:Cardiac Glycosides; D010277:Parasympathomimetics; D013566:Sympathomimetics; D001285:Atropine